Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCE-B05 in Advanced Solid Tumors
NCT07362888Phase 1Recruiting
- Sponsor
- Adcendo
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ADCE-B05 in solid tumor, sponsored by Adcendo. Primary endpoints: Maximum Tolerated Dose at 11 months and Safety and Tolerability at 18 months. Started Mar 2026; status: recruiting.
02
Drugs
ADCE-B05
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07362888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07362888.